The Heart of Innovation: How Cardiovascular Real-World Data Is Reshaping Research and Drug Development

Cardiovascular disease remains the leading cause of death worldwide, yet many research efforts still rely on narrow, trial-based populations that don't reflect the realities of care. As life sciences teams push for more inclusive, impactful innovation, real-world cardiovascular data is playing a critical role in closing the gap between clinical trials and clinical practice.

This session explores how high-quality cardiovascular RWD is driving more representative studies, uncovering long-term safety signals, and helping life sciences organizations evaluate real-world effectiveness—especially in complex, comorbid populations. 

Drawing on Veradigm’s robust cardiology dataset—developed in collaboration with the American College of Cardiology—we’ll highlight how access to rich, structured and unstructured clinical data can accelerate study design, support outcomes research, and reveal opportunities for therapeutic differentiation.

By putting the realities of patient care at the center, cardiovascular RWD is not just a supplement to traditional evidence—it’s becoming the foundation for next-generation discovery.  

Key takeaways:  

• How cardiovascular real-world data (RWD) enhances study representativeness beyond traditional clinical trials  
• The value of RWD in detecting long-term safety signals and assessing real-world treatment effectiveness  
• The benefits of linking structured and NLP tables from unstructured EHR data with claims for deeper insights  
• Why cardiovascular RWD is becoming essential to innovation in drug development and outcomes research